CAJ | 학술논문

目的探讨多药耐药基因1( MDR1)单核苷酸多态性(SNP)对肝细胞肝癌(HCC)行肝动脉栓塞化疗(TACE)的预后价值.方法以78例HCC行TACE术患者为对象,同时建立80例对照组,聚合酶链反应-限制性片段长度多态性(PCR-RFLP)法检测其静脉血标本C1236T、C3435T、G2677T/A的SNP,比较分析各SNP与HCC临床指标及TACE预后的关系.结果 HCC组与对照组的基因分布差异无统计学意义(P＞0.05)；3个位点中,仅C3435T SNP与TACE术后生存死亡明显相关(x2 =9.015,P＜0.05),中位生存时间TT型478 d,CT型382 d,CC型260d,TT型死亡的风险是CC型的0.062倍.结论 C3435T SNP是HCC行TACE术的独立预后因子,并为术中化疗药的个体化使用提供参考.
목적 탐토다약내약기인1( MDR1)단핵감산다태성(SNP)대간세포간암(HCC)행간동맥전새화료(TACE)적예후개치.방법 이78례HCC행TACE술환자위대상,동시건립80례대조조,취합매련반응-한제성편단장도다태성(PCR-RFLP)법검측기정맥혈표본C1236T、C3435T、G2677T/A적SNP,비교분석각SNP여HCC림상지표급TACE예후적관계.결과 HCC조여대조조적기인분포차이무통계학의의(P＞0.05)；3개위점중,부C3435T SNP여TACE술후생존사망명현상관(x2 =9.015,P＜0.05),중위생존시간TT형478 d,CT형382 d,CC형260d,TT형사망적풍험시CC형적0.062배.결론 C3435T SNP시HCC행TACE술적독립예후인자,병위술중화료약적개체화사용제공삼고.
Objective To investigate the prognostic value of multidrug resistance gene 1 ( MDR1 ) single nucleotide polymorphism (SNP) for transcatheterartery chemoembolization ( TACE ).Methods Samples were taken from 78 patients suffered hepatocellular carcinoma ( HCC ),C1236T,C3435T,G2677T/A SNP was detected by blood specimens adopting polymerase chain reaction-restricted fragment length polymorphism (PCR-RFLP),the association between SNP and clinical variables,prognosis of TACE was analyzed.Meanwhile,80 blood specimens were obtained as control group.Results There was no significance of the gene type incidence between HCC and control group ( P ＞ 0.05 ).In these gene locus,only C3435T SNP obviously correlated to survival or dead of HCC after TACE (x2 =9.015,P ＜0.05),the media survival for TT genetype were 478 days,while CT 382 days,CC 260 days,the death risk of TT group was 0.062 times compared with CC group.Conclusion C3435T SNP was a independence prognostic marker for HCC survival after TACE,and the study provided the reference value for individualizing chemotherapy during TACE.